A Multi-center, Randomized, Open-label, Active-controlled, Parallel-group, Phase III Study to Compare the Efficacy and Safety of JTZ-951 With Darbepoetin Alfa in Anemic Patients With Chronic Kidney Disease Receiving Maintenance Hemodialysis
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Enarodustat (Primary) ; Darbepoetin alfa
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Sponsors JW Pharmaceutical
Most Recent Events
- 19 Mar 2021 Status changed from recruiting to completed.
- 06 Oct 2020 Planned End Date changed from 1 Jun 2020 to 1 Mar 2021.
- 06 Oct 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Mar 2021.